Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02059291 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
NCT02059291 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 203 participants.
The verdict
NCT02059291, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
Study Summary
This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.
Interventions
- DRUG Placebo
- DRUG Canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2014-06-27 |
| Est. Completion | 2017-07-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02059291
The ClinicalTrials.gov registry entry for NCT02059291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02059291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02059291 about?
NCT02059291 is a clinical study titled "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers". This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.
What is the current status of trial NCT02059291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2014-06-27. Estimated completion is 2017-07-04.
What interventions are being tested in trial NCT02059291?
The interventions under investigation include: Placebo (DRUG), Canakinumab (DRUG).
Who is sponsoring clinical trial NCT02059291?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.